COMMUNIQUÉS West-GlobeNewswire

Cronos’ brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes
02/09/2026
TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is expanding its lineup of edible multipacks with the SOURZ by Spinach ® Blue [...]
Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.
02/09/2026
Agreement broadens access to revyve® advanced wound care products through an established Canadian medical supply distributor WINNIPEG, Manitoba, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “ [...]
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
02/09/2026
~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene inilparvovec in the U.K. ~ ~ Both submissions are supported by the three-year data analysis from the Phase I/II study, [...]
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
02/09/2026
-- Significant New Program Positioned to Become One of Lifecore’s Largest Contracts -- -- Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Drug Product -- -- Program Expected to [...]
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
02/09/2026
Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage vs placebo following a single [...]
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
02/09/2026
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional analyses evaluating [...]
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
02/09/2026
Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea’s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth [...]
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
02/09/2026
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
By Popular Demand: Tilray Beverages Makes Popsicle Hard Firecracker a Permanent Flavor
02/09/2026
After a limited-edition launch sparked strong consumer demand, the nostalgic red-white-and-blue flavor joins the Popsicle Hard lineup year-round NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray [...]
Resalis Therapeutics Appoints Diana M. Røpcke as Chief Medical Officer
02/09/2026
Dr. Røpcke joins Resalis with extensive experience in clinical drug development as well as expertise in obesity and cardiometabolic therapy areas Torino, Italy, September 2, 2026 – Resalis Therapeutics , a biotechnology [...]
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
02/09/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”) today announced that, following the recent issuance of shares and the exercise of [...]
DoKegel Launches Personalized Pelvic Floor Training App for Men
02/09/2026
New DoKegel App Turns a Short Quiz Into a Daily Kegel Routine NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- DoKegel has launched a men's wellness app built around personalized Kegel exercises. The app pairs guided pelvic [...]
NewBiologix and Synastra Biotechnology Partner to Advance Stable rAAV Manufacturing for Duchenne Muscular Dystrophy Gene Therapy
02/09/2026
Collaboration will use NewBiologix’s Xcell™ platform to establish a scalable manufacturing foundation for Synastra’s investigational DMD gene therapy program LAUSANNE, Switzerland, Sept. 02, 2026 (GLOBE NEWSWIRE) -- [...]
Levicept Announces Attendance at Cantor and Jefferies Global Healthcare Conferences
02/09/2026
SANDWICH, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class clinical-stage treatment for osteoarthritis (OA), today [...]
Novonesis to build next generation enzyme production facility in India
02/09/2026
Novonesis will invest €600 million to expand its site in  Patalganga  and build a state-of-the-art facility. This marks another step in the company's long-term growth strategy and continued investment in its global [...]
Nicox Announces Extension of Cash Runway
02/09/2026
Press Release Nicox Announces Extension of Cash Runway Cash position, of €8.4 million 1 as of 31 August 2026, sufficient to fund existing operations beyond Q1 2028 NCX 470 U.S. NDA approval milestone would fund [...]
Nicox annonce l’extension de son horizon de trésorerie
02/09/2026
Communiqué de presse Nicox annonce l’extension de son horizon de trésorerie Position de trésorerie de 8.4 millions d’euros 1 au 31 août 2026 , suffisante pour financer les opérations actuelles au-delà du 1er trimestre [...]
IBA joins PFAROS European initiative to advance PFAS destruction for healthcare and pharmaceutical applications
02/09/2026
Louvain-la-Neuve, Belgium, 2 September 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its participation in PFAROS, a new European research [...]
IBA rejoint l’initiative européenne PFAROS pour accélérer le développement de solutions de destruction des PFAS dans les secteurs de la santé et de la pharmacie
02/09/2026
Louvain ‑ la ‑ Neuve, Belgique, le 2 septembre 2026, 7h00 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélérateurs de particules, annonce aujourd’hui sa participation à PFAROS, [...]

Pages